Abivax S.A.

Abivax has spent heavily on advancing obefazimod through late-stage trials for ulcerative colitis (UC) and is eagerly awaiting a readout to see whether its faith in the compound will translate into a

With a star pipeline candidate entering Phase III clinical trials for the treatment for ulcerative colitis, Abivax S.A. is in the midst of a corporate rework to be able to secure funding and ultimat

AstraZeneca PLC has discontinued its anti-IL-23 monoclonal antibody, brazikumab, for inflammatory bowel diseases (IBD) as the market and pipeline become increasingly crowded and following unavoidable

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip 's global team, in this podcast version of Five Must-Know Things. This ep